Avicanna Inc.
Condensed Consolidated Interim Financial Statements
Unaudited
For the Three Months Ended March 31, 2023, and 2022
(Expressed in Canadian dollars)

Avicanna Inc.
Condensed Consolidated Interim Statements of Financial Position
Unaudited
(Expressed in Canadian Dollars)

	Note		March 31, 2023		December 31, 2022
ASSETS					
Current assets					
Cash		$	221,875	$	1,194,040
Amounts receivable	4		2,457,634		2,149,371
Prepaid assets			881,234		480,978
Biological assets	5		1,876		129,824
Inventory	6		3,434,961		3,110,205
Total current assets			**6,997,580**		**7,064,418**
Right of use asset	9		336,307		369,827
Property and equipment	7		10,371,765		10,017,358
Intangible assets	8		144,377		167,628
Total assets		**$**	**17,850,029**	**$**	**17,619,231**
LIABILITIES AND SHAREHOLDERS' EQUITY					
Current liabilities					
Trade payables and accrued liabilities		$	4,689,453	$	4,752,796
Lease liability – current portion	12		150,248		150,248
Loan payable – current portion	14		303,596		796,846
Convertible debentures	13		1,025,147		1,861,201
Derivative liability	15		17,551		972
Due to related party	16		4,192,795		3,843,196
Total current liabilities			**10,378,790**		**11,405,259**
Lease liability	12		191,130		221,873
Loan payable	14		137,891		179,551
Deferred revenue	11		2,249,914		2,353,897
Total liabilities			**12,957,725**		**14,160,580**
Shareholders' Equity					
Share capital	17		78,319,595		74,894,122
Warrants	17		11,921,713		11,714,410
Share-based payment reserve	18		6,526,898		6,808,009
Accumulated other comprehensive loss			(2,343,938)		(2,970,864)
Deficit			(93,251,368)		(90,829,237)
Equity attributable to owners of the parent			1,172,900		(383,560)
Non-controlling interest	19		3,719,404		3,842,211
Total equity			**4,892,304**		**3,458,651**
Total liabilities and shareholders' equity		**$**	**17,850,029**	**$**	**17,619,231**

Nature of operations and going concern uncertainty – Note 1

Approved by the Board
/s/ Dr. Chandra Panchal, Chairman of the Board of Directors /s/ John McVicar, Audit Committee Chair, Director

The accompanying notes are an integral part of these condensed consolidated interim financial statements

Avicanna Inc.
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss
For the Three Months Ended March 31, 2023, and 2022
Unaudited
(Expressed in Canadian Dollars)

		For the Three Months Ended March 31,			
	Notes		**2023**		**2022**
Revenue					
Service Revenue		$	26,774	$	-
License Revenue	11		173,412		100,750
Product Sales			970,032		937,211
Total Revenue			**1,170,218**		**1,037,961**
Cost of goods sold			(677,628)		(637,316)
Gross margin before the undernoted			**492,590**		**400,645**
Inventory (impairment) recovery	6		(152,607)		43,564
Fair value changes in biological assets included in inventory sold			(2,353)		23,752
Unrealized gain on changes in fair value of biological assets	5		250,326		1,332,526
Gross margin			**587,956**		**1,800,487**
Expenses					
General and administrative	21		1,777,902		2,045,487
Share-based compensation	18		997,467		153,242
Depreciation and amortization	7,8,9		157,931		253,470
Expected credit loss	20		16,454		-
Total Expenses			**(2,949,754)**		**(2,452,199)**
Other income (expenses)					
Foreign exchange loss			(8,209)		(10,504)
Gain on disposal of capital assets			2,414		-
Gain on fair value of derivative liability	15		39,234		50,956
Other income			40,457		34,238
Interest expense	13,14		(56,887)		(80,438)
Accretion of loans and convertible debentures	13,14		(163,566)		(281,616)
Net Loss		**$**	**(2,508,355)**	**$**	**(939,076)**
Exchange differences on translation of foreign operations			590,343		1,582,963
Comprehensive loss/Income		**$**	**(1,918,012)**	**$**	**643,887**
Comprehensive loss attributable to non – controlling interest	19		(122,807)		741,106
Comprehensive loss attributable to Shareholders of the Company			(1,795,205)		(97,219)
		$	**(1,918,012)**	**$**	**643,887**
Weighted average number of common shares – basic and diluted			75,802,901		45,973,986
Comprehensive loss per share – basic and diluted		$	(0.03)	$	0.01

The accompanying notes are an integral part of these condensed consolidated interim financial statements

Avicanna Inc.
Condensed Consolidated Interim Statements of Changes in Shareholders' Equity
For the Three Months Ended March 31, 2023, and 2022
Unaudited
(Expressed in Canadian Dollars)

		Common shares		Warrants	Share-based payment Reserve	Deficit	Accumulated other comprehensive loss	Non-controlling interest	Total
	Note	#	$	$	$	$	$	$	$
December 31, 2022		**74,952,800**	**74,894,122**	**11,714,410**	**6,808,009**	**(90,829,237)**	**(2,970,864)**	**3,842,211**	**3,458,651**
Share based compensation	18	-	-	-	997,467	-	-	-	997,467
Settlement of RSUs	17,18	2,959,445	1,530,384	-	(1,278,578)	-	-	-	251,806
Issuance of units	17	3,096,230	1,019,089	207,303	-	-	-	-	1,226,392
Conversion debentures	13,17	2,190,000	876,000	-	-	-	-	-	876,000
Foreign exchange translation		-	-	-	-	-	626,926	(36,583)	590,343
Net loss		-	-	-	-	(2,422,131)	-	(86,224)	(2,508,355)
March 31, 2023		**83,198,475**	**78,319,595**	**11,921,713**	**6,526,898**	**(93,251,368)**	**(2,343,938)**	**3,719,404**	**4,892,304**
December 31, 2021		**45,884,282**	**66,243,911**	**9,621,935**	**6,847,200**	**(77,407,467)**	**(4,159,392)**	**5,761,835**	**6,908,022**
Share based compensation	18	-	-	-	153,242	-	-	-	153,242
Exercise of RSUs	18	376,875	424,593	-	(424,593)	-	-	-	-
Issuance of units	17	7,210,194	1,959,837	531,231	-	-	-	-	2,491,068
Warrants issued with debentures	13,17	-	-	206,255	-	-	-	-	206,255
Foreign exchange translation		-	-	-	-	-	1,268,350	314,613	1,582,563
Net loss		-	-	-	-	(1,365,569)	-	426,493	(939,076)
March 31, 2022		**53,471,351**	**68,628,341**	**10,359,421**	**6,575,849**	**(78,773,036)**	**(2,891,042)**	**6,502,941**	**10,402,474**

The accompanying notes are an integral part of these condensed consolidated interim financial statements

Avicanna Inc.
Condensed Consolidated Interim Statements of Cash Flow
For the Three Months Ended March 31, 2023, and 2022
Unaudited
(Expressed in Canadian Dollars)

		For the Three-months ended March 31,	
	Note	**2023**	**2022**
Cash flows from operating activities			
Net loss		$ (2,508,355)	$ (939,076)
Depreciation and amortization	7,8,9	157,931	253,470
Accretion of loans and convertible debentures	13,14	163,566	284,385
Share-based compensation	18	997,467	153,242
Gain on fair value of derivative liability	15	(39,234)	(50,956)
Deferred revenue incurred, net of recognized revenue	11	(103,983)	(100,750)
Expected credit losses	4	16,454	-
Gain on sale of capital assets		(2,414)	-
Changes in non-cash operating elements of working capital	23	(733,318)	(2,742,234)
Cash used in operating activities		**(2,051,886)**	**(3,141,919)**
Cash flows from investing activities			
Purchase of capital assets	7	(16,447)	(29,567)
Proceeds from disposal of capital assets		26,587	-
Proceeds from sale of investments	10	-	180,000
Cash provided by investing activities		**10,140**	**150,433**
Cash flows from financing activities			
Payment of lease liability	12	(37,563)	(56,238)
Proceeds from issuance of common shares, net of costs	17	1,226,392	2,491,068
Increase (decrease) in balance due to related party	16	171,543	(190,779)
Repayment of loan payable	14	(514,913)	(584,015)
Issuance of debentures	13	-	1,473,238
Cash provided by financing activities		**845,459**	**3,133,274**
Net increase (decrease) in cash		**(1,196,287)**	**141,788**
Effect of foreign exchange differences		224,122	1,402,828
Cash, beginning of period		1,194,040	31,004
Cash, end of period		**$ 221,875**	**$ 1,575,620**

The accompanying notes are an integral part of these condensed consolidated interim financial statements

NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3(3) (a), if an auditor has not performed a review of the condensed consolidated interim financial statements, they must be accompanied by a notice indicating that the interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed consolidated interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these condensed consolidated interim financial statements in accordance with standards established by the Chartered Professional Accountants Canada for a review of interim financial statements by an entity's auditor.

1. NATURE OF OPERATIONS AND GOING CONCERN UNCERTAINTY

Avicanna Inc. ("Avicanna" or the "Company") was incorporated in Ontario, Canada. Avicanna is a Canadian vertically integrated biopharmaceutical company developing and driving biopharmaceutical advancements of plant-derived cannabinoid-based products with operations in both North and South America. To date, the Company has commercialized several product lines in both North and South America.

The registered office of the Company is located at 480 University Avenue, Suite 1502, Toronto, Ontario. The Company's common shares are listed under the symbol "AVCN" on the Toronto Stock Exchange ("TSX"); the OTC US exchange under the symbol "AVCNF"; and the Frankfurt Stock Exchange under the symbol "0NN".

These condensed consolidated interim financial statements have been prepared on a going concern basis which contemplates that the Company will continue operations for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. These condensed consolidated interim financial statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern.

As of March 31, 2023, the Company has an accumulated deficit of $93,251,368 (December 31, 2022 - $90,829,237), cash of $221,875 (December 31, 2022 – $1,194,040), and a working capital deficit of $3,381,210 (December 31, 2022 – deficit of $4,340,841). Additionally, the Company incurred a net loss after taxes of $2,508,355 and used $2,051,886 of cash from operating activities during the three months ended on March 31, 2023. During the three months ended March 31, 2022, the Company incurred a net loss of $939,076 and used $3,141,919 of cash from operating activities during the same period. The Company will need to raise additional financing to continue operations, product development and clinical research. Although the Company has been successful in the past in obtaining financing and it believes that it will continue to be successful, there is no assurance that it will be able to obtain adequate financing in the future or that such financing will be available on terms that are advantageous to the Company. These material uncertainties may cast significant doubt as to the Company's ability to continue as a going concern.

2. BASIS OF PRESENTATION

Statement of compliance

These condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard 34 – Interim Financial Reporting ("IAS 34") using accounting policies consistent with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). Accordingly, certain disclosures normally included in annual financial statements prepared in accordance with IFRS have been omitted or condensed. These condensed consolidated interim financial statements should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, 2022.

These condensed consolidated interim financial statements were approved and authorized for issuance by the Company's Board of Directors on May 15, 2023.

Basis of presentation

These condensed consolidated interim financial statements have been prepared on a historical cost basis except for biological assets and derivative financial instruments, which are measured at fair value through profit and loss, as explained in the accounting policies below. The Company operates in four business segments: three based on geographic region; North America, South America and Rest of World, and Corporate, which is comprised of costs which serve the Company's global administrative responsibilities.

Functional and presentation currency

These condensed consolidated interim financial statements are presented in Canadian dollars, which is the functional currency of the Company. The functional currency of each subsidiary is presented in the table below.

(Expressed in Canadian dollars)

2. BASIS OF PRESENTATION (CONTINUED)

Basis of consolidation

Subsidiaries are entities controlled by the Company. Control exists when the Company has power, directly or indirectly, over an entity and is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through the power it has. The financial statements of subsidiaries are included in the condensed consolidated interim financial statements from the date that control commences until the date that control ceases. The following is a list of the Company's operating subsidiaries.

Subsidiaries	Jurisdiction of Incorporation	Ownership Interest	Functional currency
Avicanna (UK) Limited ("Avicanna UK")	United Kingdom	100%	British Pound Sterling
Avicanna USA Inc. ("Avicanna USA")	United States of America	100%	United States Dollar
2516167 Ontario Inc. ("My Cannabis")	Ontario, Canada	100%	Canadian Dollar
Sigma Magdalena Canada Inc.	Ontario, Canada	60%	Canadian Dollar
Sigma Analytical Magdalena S.A.S. ("Sigma Colombia")	Republic of Colombia	60%	Colombian Peso
Santa Marta Golden Hemp S.A.S. ("SMGH")	Republic of Colombia	60%	Colombian Peso
Sativa Nativa S.A.S. ("SN")	Republic of Colombia	0%*	Colombian Peso
Avicanna LATAM S.A.S. ("LATAM")	Republic of Colombia	100%	Colombian Peso

*The Company disposed of SN on June 29, 2022. Prior to this, the Company held ownership of 63% (Note 24).

Intragroup balances, and any unrealized gains and losses or income and expenses arising from transactions with jointly controlled entities are eliminated to the extent of the Company's interest in the entity.

Subsequent to acquisition, the carrying amount of non-controlling interests is the amount recognized initially, plus the non-controlling interests' share of changes in the capital of the company in addition to changes in ownership interests. Total comprehensive income or loss is attributed to non-controlling interests, even if this results in the non-controlling interests having a deficit balance.

Foreign currency transactions

Foreign currency transactions are translated into Canadian dollars at exchange rates in effect on the date of the transactions. At the end of each reporting period, monetary assets and liabilities denominated in foreign currencies are translated into Canadian dollars at the foreign exchange rate applicable at that period-end date. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Foreign currency differences are generally recognized in profit or loss and presented within gain (loss) on foreign exchange.

Foreign currency translation

The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, are translated into Canadian dollars at the exchange rates at the reporting date. The income and expenses of foreign operation are translated into Canadian dollars at the dates of the transactions. Foreign currency differences due to translation are recognized in other comprehensive income ("OCI") and accumulated in the translation reserve, except to the extent that the translation difference is allocated to non-controlling interests ("NCI").

Use of judgments, estimates and assumptions

The preparation of the condensed consolidated interim financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income, and expenses. Actual results may differ from these estimates.

Estimates are based on management's best knowledge of current events and actions that the Company may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The following are the critical judgments and estimates that management have made in the process of applying the Company's accounting policies and that have the most significant effect on the amounts recognized in the Condensed consolidated interim financial statements:

2. BASIS OF PRESENTATION (CONTINUED)

Business combinations
Determining whether an acquisition meets the definition of a business combination or represents an asset purchase requires judgment on a case-by-case basis. As outlined in IFRS 3, the components of a business must include inputs, processes and outputs.

In a business combination, substantially all identifiable assets, liabilities and contingent liabilities acquired are recorded at the date of acquisition at their respective fair values. One of the most significant areas of judgment and estimation relates to the determination of the fair value of these assets and liabilities, including the fair value of contingent consideration, if applicable. If any intangible assets are identified, depending on the type of intangible asset and the complexity of determining its fair value, the Company may utilize an independent external valuation expert to develop the fair value, using appropriate valuation techniques, which are generally based on a forecast of the total expected future net cash flows. These valuations are linked closely to the assumptions made by management regarding the future performance of the assets concerned and any changes in the discount rate applied.

Biological assets and inventory
In calculating the fair value of the biological assets and inventory, management is required to make a number of estimates, including estimating the stage of growth of the cannabis up to the point of harvest, harvesting costs, selling costs, average or expected selling prices and list prices, expected yields for the cannabis plants, and oil conversion factors. Inventories of harvested cannabis are valued at the lower of cost or net realizable value. The Company estimates the net realizable value of inventories, considering the most reliable evidence available at the reporting date. The future realization of these inventories may be affected by market-driven changes that may reduce future selling prices. A change to these assumptions could impact the Company's inventory valuation and gross profit.

Estimated useful life of long-lived assets
Judgment is used to estimate each component of a long-lived asset's useful life and is based on an analysis of all pertinent factors including, but not limited to, the expected use of the asset and in the case of an intangible asset, contractual provisions that enable renewal or extension of the asset's legal or contractual life without substantial cost, and renewal history. If the estimated useful lives were incorrect, it could result in an increase or decrease in the annual amortization expense, and future impairment charges or recoveries.

Impairment of long-lived assets
When there are indications that an asset may be impaired, the Company is required to estimate the asset's recoverable amount. The recoverable amount is the greater of value in use and fair value less costs to sell. Fair value is determined as the amount that would be obtained from the sale of the asset in an arm's length transaction between knowledgeable and willing parties. Determining the value in use requires the Company to estimate expected future cash flows associated with the assets and a suitable discount rate to calculate present value.

In addition to assessing evidence of possible impairment, the Company also determines whether there is any indication that a previously recognized impairment loss for an asset other than goodwill no longer exists or may have decreased. The Company determines whether there has been a change in the estimate used to determine the asset's recoverable amount since the last impairment loss is recognized.

Fair value measurements
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

2. BASIS OF PRESENTATION (CONTINUED)

Functional currency

The functional currency for each of the Company's subsidiaries is the currency of the primary economic environment in which the respective entity operates. Such determination involves certain judgements to identify the primary economic environment. The Company reconsiders the functional currency of its subsidiaries if there is a change in events and/or conditions which determine the primary economic environment.

Provisions

Provisions are accrued for liabilities with uncertain timing or amounts, if, in the opinion of management, it is both likely that a future event will confirm that a liability had been incurred at the date of the condensed consolidated interim financial statements and the amount can be reasonably estimated. In cases where it is not possible to determine whether such a liability has occurred, or to reasonably estimate the amount of loss until the performance of some future event, no accrual is made until that time. In the ordinary course of business, the Company may be party to legal proceedings which include claims for monetary damages asserted against the Company. The adequacy of provisions is regularly assessed as new information becomes available.

Leases

The Company exercises judgment when contracts are entered into that may give rise to a right-of-use asset that would be accounted for as a lease. Judgment is required in determining the appropriate lease term on a lease-by-lease basis. The Company considers all facts and circumstances that create an economic incentive to exercise a renewal option or to not exercise a termination option at inception and over the term of the lease, including investments in major leaseholds, operating performance, and changed circumstances. The periods covered by renewal or termination options are only included in the lease term if the Company is reasonably certain to exercise that option.

Income tax provisions

Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. Judgment is required in determining whether deferred income tax assets and liabilities are recognized on the consolidated statement of financial position. Deferred income tax assets, including those arising from unutilized tax losses, require management to assess the likelihood that the Company will generate future taxable income in order to utilize the deferred income tax assets. Estimates of future taxable income are based on forecasted cash flows from operations or other activities. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred income tax assets recorded on the reporting date could be impacted.

The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the final outcome of these tax-related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made.

Determination of share-based payments

The estimation of share-based payments (including warrants and stock options) requires the selection of an appropriate valuation model and consideration as to the inputs necessary for the valuation model chosen. The model used by the Company is the Black-Scholes valuation model at the date of the grant. The Company makes estimates as to the volatility, the expected life, dividend yield and the time of exercise, as applicable. The expected volatility is based on the average volatility of share prices of similar companies over the period of the expected life of the applicable warrants and stock options. The expected life is based on historical data. These estimates may not necessarily be indicative of future actual patterns.

3. SIGNIFICANT ACCOUNTING POLICIES

These condensed consolidated interim financial statements have been prepared in accordance with the accounting policies adopted in the Company's most recent audited consolidated financial statements for the year ended December 31, 2022.

(Expressed in Canadian dollars)

4. AMOUNTS RECEIVABLE

		March 31, 2023		December 31, 2022
Trade and other receivables	$	1,965,414	$	2,121,619
Sales tax receivable		833,182		783,634
Expected credit loss provision		(340,962)		(755,882)
Total amounts receivable	**$**	**2,457,634**	**$**	**2,149,371**

5. BIOLOGICAL ASSETS

Biological assets consist of cannabis on plants. The changes in the carrying value of biological assets are as follows:

		March 31, 2023		December 31, 2022
Opening balance	$	129,824	$	1,083,448
Production costs capitalized		139,582		428,775
Gain in fair value less costs to sell due to biological transformation		253,521		1,535,123
Transferred to inventory upon harvest		(526,992)		(2,798,963)
Foreign exchange translation		5,941		(118,559)
Ending balance	**$**	**1,876**	**$**	**129,824**

The Company measures its biological assets at their fair value less costs to sell. This is determined using a model which estimates the expected harvest yield in grams for plants and seeds currently being cultivated, and then adjusts that amount for the expected selling price less costs to sell per gram. During the period, the Company also cultivated seeds which have been transferred into inventory.

The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company's method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest.

The following table quantifies each significant unobservable input and provides the impact that a 10% increase/decrease in each input would have on the fair value of biological assets.

Assumptions: CBD Isolate	As of March 31, 2023		As of December 31, 2022	
	Input	Effect on Fair Value	Input	Effect on Fair Value
CBD Isolate Yield	4.4%	($26,893)	4.3%	($6,915)
CBD Isolate Price (USD/KG)	1,476	($27,182)	$1,615	($7,192)
Weighted average of expected loss of plants until harvest [i]	19.9%	$1,250	0.0%	$856
Expected yields for cannabis plants (average grams per plant)	154	$5,510	151	$3,600
Weighted average number of growing weeks completed as a percentage of total growing weeks as at period end	67.0%	$5,510	34.0%	$3,600
Estimated fair value less costs to complete and sell (per gram) [ii]	($0.06)	$4,122	($0.03)	$2,061
After harvest cost to complete and sell (per gram)	$0.03	$1,388	$0.05	$1,539

(Expressed in Canadian dollars)

5. BIOLOGICAL ASSETS (CONTINUED)

Assumptions: THC Resin	As of March 31, 2023		As of December 31, 2022	
	Input	Effect on Fair Value	Input	Effect on Fair Value
THC Resin Yield	-	-	12.9%	$31,051
THC Resin Price (USD/KG)	-	-	$5,189	$246,876
Weighted average of expected loss of plants until harvest [i]	-	-	10.0%	$15,717
Expected yields for cannabis plants (average grams per plant)	-	-	151	$30,853
Weighted average number of growing weeks completed as a percentage of total growing weeks as at period end	-	-	56.0%	$3,608
Estimated fair value less costs to complete and sell (per gram) [ii]	-	-	$0.95	$31,051
After harvest cost to complete and sell (per gram)	-	-	$0.01	$17,032

[i] Weighted average of expected loss of plants until harvest represents loss via plants that do not survive to the point of harvest. It does not include any financial loss on a surviving plant.

[ii] The estimated fair value less costs to complete and sell (per gram/unit) represents the expected sales price for the Company's active ingredients including isolate and resins less the remaining costs to complete and sell that product as finished product which is inclusive of all production activities.

These estimates are subject to volatility in market prices and several uncontrollable factors, which could significantly affect the fair value of biological assets in future periods.

The Company estimates the harvest yields for cannabis at various stages of growth. As of March 31, 2023, it is expected that the Company's cannabis plants biological assets will yield approximately 1,040,461 grams of dry cannabis (December 31, 2022 – 2,378,005 grams) and 322,932 seeds (December 31, 2022 – nil seeds).

The Company's estimates are, by their nature, subject to change and differences from the anticipated yield will be reflected in the gain or loss on biological assets in future periods.

An unrealized gain on biological assets of $250,326 was included in costs of goods sold for the three months ended March 31, 2023 (March 31, 2022 - $1,332,526).

(Expressed in Canadian dollars)

6. INVENTORY

	Capitalized Cost	Biological assets fair value adjustment	Impairment	Carrying Value
Harvested Cannabis				
Seeds	$ 305,721	$ -	$ (305,721)	$ -
Wet Flower	42,667	124,223	(94,200)	72,690
Dried Flower	447,937	2,804,612	(2,255,532)	997,017
	796,325	**2,928,835**	**(2,655,453)**	**1,069,707**
Active Pharmaceutical Ingredients				
Work in process	683,562	852,789	(805,929)	730,123
Finished goods	5,972	(29,822)	23,850	-
	689,534	**822,967**	**(782,079)**	**730,123**
Supplies and consumables	**1,333,953**	**-**	**(382,806)**	**951,147**
Finished goods	**699,691**	**-**	**(15,707)**	**683,984**
March 31, 2023	**$ 3,519,503**	**$ 3,751,802**	**$ (3,836,345)**	**$ 3,434,961**

	Capitalized Cost	Biological assets fair value adjustment	Impairment	Carrying Value
Harvested Cannabis				
Seeds	$ 293,649	$ -	$ (293,649)	$ -
Dried Flower	470,660	2,419,287	(2,288,174)	601,773
	764,309	**2,419,287**	**(2,581,823)**	**601,773**
Active Pharmaceutical Ingredients				
Work in process	515,681	716,997	(397,396)	835,282
Finished goods	86,719	73,380	(160,099)	-
	602,400	**790,377**	**(557,495)**	**835,282**
Supplies and consumables	**1,473,859**	**-**	**(366,055)**	**1,107,804**
Finished goods	**580,366**	**$ -**	**$ (15,020)**	**$ 565,346**
December 31, 2022	**$ 3,420,934**	**$ 3,209,664**	**$ (3,520,393)**	**$ 3,110,205**

The value of inventory transferred to cost of goods sold during the three months ended March 31, 2023, was $677,628 (March 31, 2022 - $637,316). For the three months ended March 31, 2023, the Company recognized inventory impairment of $152,607 (March 31, 2022 – recovery of $43,564).

(Expressed in Canadian dollars)

7. PROPERTY AND EQUIPMENT

	Equipment $	Land $	Construction in Progress $	Infrastructure and Buildings $	Total $
Cost					
December 31, 2022	4,351,599	5,691,073	180,674	1,331,702	11,555,048
Additions	16,447	-	-	-	16,447
Disposals	(24,173)	-	-	-	(24,173)
Foreign exchange translation	166,476	260,426	8,268	56,443	491,613
March 31, 2023	**4,510,349**	**5,951,499**	**188,942**	**1,388,145**	**12,038,935**
Accumulated Depreciation					
December 31, 2022	1,329,710	-	-	207,980	1,537,690
Depreciation	82,233	-	-	18,870	101,104
Foreign exchange translation	23,303	-	-	5,074	26,376
March 31, 2023	**1,435,246**	**-**	**-**	**231,924**	**1,667,170**
Net Book Value					
December 31, 2022	3,021,889	5,691,073	180,674	1,123,722	10,017,358
March 31, 2023	**3,075,103**	**5,951,499**	**188,942**	**1,156,221**	**10,371,765**

During the three months ended March 31, 2023, the Company recognized depreciation expense on its property and equipment of $101,103 (March 31, 2022 - $166,943).

8. INTANGIBLE ASSETS

	Customer Relationships $	Ecommerce Platform $	Licenses and Permits $	Software Licenses $	Intellectual Property $	Total $
Cost						
December 31, 2022	141,327	455,994	38,783	93,535	80,163	809,802
Additions	-	-	-	-	-	-
Foreign exchange translation	-	-	1,775	4,326	3,622	9,723
March 31, 2023	**141,327**	**455,994**	**40,558**	**97,861**	**83,785**	**819,525**
Accumulated Amortization						
December 31, 2022	141,327	288,366	38,783	93,535	80,163	642,174
Amortization	-	23,308	-	-	-	23,308
Foreign exchange translation	-	(57)	1,775	4,326	3,622	9,666
March 31, 2023	**141,327**	**311,617**	**40,558**	**97,861**	**83,785**	**675,148**
Net Book Value						
December 31, 2022	-	167,628	-	-	-	167,628
March 31, 2023	**-**	**144,377**	**-**	**-**	**-**	**144,377**

During the three months ended March 31, 2023, the Company recognized amortization on its intangible assets of $23,308 (March 31, 2022 - $37,462).

(Expressed in Canadian dollars)

9. RIGHT OF USE ASSETS

As of March 31, 2023, and December 31, 2022, the Company's right of use assets consisted of the following:

		March 31, 2023		December 31, 2022
Cost				
Opening balance	$	392,297	$	670,549
Lease expiration		-		(670,549)
Additions		-		392,297
Ending balance	$	392,297	$	392,297
Accumulated Amortization				
Opening balance	$	22,470	$	523,357
Lease expiration		-		(670,549)
Depreciation		33,520		169,662
Ending balance	$	55,990	$	22,470
Net Book Value	**$**	**336,307**	**$**	**369,827**

During the three months ended March 31, 2023, the Company recognized depreciation on its right of use assets of $33,520 (March 31, 2022 - $49,065).

10. LONG-TERM INVESTMENTS

		March 31, 2023		December 31, 2022
Balance at the beginning of the year	$	-	$	180,000
Disposition of long-term investment		-		(180,000)
Ending balance	**$**	**-**	**$**	**-**

Long-term investments consist of 720,000 shares in Southern Sun Pharma ("Southern Sun") purchased for a total cost of $72. During the year ended December 31, 2020, Southern Sun completed a financing through the sale of units at $1.25 per unit. Each unit was comprised of one common share and one-half common share purchase warrant. Each whole warrant entitled the holder to purchase an additional share at $1.50 at any time up to 18 months following the closing date. Due to this financing, the Company recognized an unrealized gain from the change in fair value of $518,141. The Company used an iterative calculation based on the Black-Scholes options pricing model to allocate the subscription price between the half-warrant and the common share. The residual value of each common share was valued at $1.08; the Company further applied a discount of 7.5 % for the lack of marketability of this investment.

On February 2, 2022, all shares owned by the Company were redeemed by Southern Sun. The shares were redeemed for $0.25 per share for gross proceeds of $180,000. During the three months ended March 31, 2023, the Company recognized a loss of $nil (March 31, 2022 - $nil) and an unrealized loss of $nil (March 31, 2022 - $nil).

(Expressed in Canadian dollars)

11. DEFERRED REVENUE

		March 31, 2023		December 31, 2022
Opening balance	$	2,353,897	$	2,782,101
Additions		-		677,916
Revenue recognized		(103,983)		(1,106,120)
Ending Balance	**$**	**2,249,914**	**$**	**2,353,897**

[i] On November 26, 2019, the Company entered into a license agreement (the "License Agreement") with LC2019, Inc. ("LC2019") pursuant to which the Company has agreed to license certain proprietary formulations and brand elements to LC2019 for commercialization in the United States. Pursuant to the terms of the License Agreement, the Company transfers brand/trademark as well as intellectual property related to product development. For LC2019 to benefit from the brand, there are activities that the Company would need to perform to support and maintain the value of the brand/ trademark. As ongoing activities are required to maintain the brand, the license to the brand/ trademark would be considered a right to access and therefore would be recognized over time. In addition, given the license is for cannabis related to product development, the Company meets the criteria for right of use of intellectual property and recognize at a point time. However, IFRS 15 states that revenue cannot be recognized for a license that provides a right to use intellectual property before the period during which the customer is able to use and benefit from the license. As cannabis remains federally illegal in the US, there exists restrictions in the benefits that the Company can derive from this license. Consequently, the revenue derived from the above license has been recorded as deferred revenue to be recognized into revenue evenly over a period of ten years. In relation to this contract, the Company recognized $94,500 as license revenue for the three months ended March 31, 2023 (March 31, 2022 - $94,500).

[ii] On August 11, 2020, the Company entered into an exclusive Distribution Agreement with a third-party, granting them the exclusive right to promote, market and sell the Company's products. The Company received $250,000 as consideration of the exclusivity partnership for a period of five years plus an automatic renewal period of five years (the "Exclusivity Fee"). The Company determined that its performance obligation with regards to the contract occurs over a period of time and therefore, revenue is to be recognized straight-line over a ten-year period based on the term of the contract and the automatic term renewal. On August 29, 2022, the Company terminated the Distribution Agreement, because the third-party had failed to meet its obligations, including failing to cure such failure, under the Distribution Agreement. As the Company no longer carries any obligation under the Distribution Agreement. The Company recognized $nil into License Revenue for the three months ended March 31, 2023 (March 31, 2022 - $6,250).

[iii] On April 10, 2022, the Company entered into an exclusive license and supply agreement with a South American pharmaceutical company (the "Licensee"). The agreement provides the Licensee with the right to use the Company's intellectual property ("IP") to promote, market and sell the Company's products within Licensee's designated territory for an initial period of five years, commencing on the date of execution. As consideration for the licensing agreement, the Company is to receive a fee of USD$1,000,000 ($1,291,255), paid in five tranches; a USD$100,000 ($125,955) fee paid on signing of the agreement and the remainder paid in four tranches as the Company meets specific milestones in the transfer of IP. The Company determined that the fee paid upon signing contains a performance obligation which occurs over a period of time and therefore, revenue is to be recognized straight-line over a five-year period based on the term of the contract. In relation to this contract, the Company recognized $6,297 into License Revenue for the three months ended March 31, 2023 (March 31, 2022 - $nil). Subsequent payments are to be recognized into revenue as each milestone has been met.

[iv] On April 22, 2022, the Company entered into an exclusive license and supply agreement with a Brazilian pharmaceutical company (the "Licensee"). The agreement provides the Licensee with the right to use the Company's IP to promote, market and sell the Company's products within the Licensee's designated territory for an initial period of 5 years, commencing on the date of execution. As consideration for the licensing agreement, the Company is to receive a fee of USD$250,000 ($322,814), paid in three tranches; a USD$50,000 ($63,713) fee paid on signing of the agreement and two USD$100,000 ($129,125) as the Licensee meets specific milestones. The Company determined that the fee paid upon signing contains a performance obligation which occurs over a period of time and therefore, revenue is to be recognized straight-line over a five-year period based on the term of the contract. In relation to this contract, the Company recognized $3,186 into License Revenue for the three months ended March 31, 2023 (March 31, 2022 - $nil). Subsequent fees are to be recognized into revenue as each milestone is met.

(Expressed in Canadian dollars)

12. LEASE LIABILITY

As of March 31, 2023, and December 31, 2022, the lease liability consisted of the following:

		March 31, 2023		December 31, 2022
Opening balance	$	**372,122**	$	**156,247**
Interest incurred on lease liability		6,820		17,330
New leases		-		392,297
Lease payments		(37,564)		(193,753)
Ending balance	$	**341,378**	$	**372,122**
Lease liability – current portion		150,248		150,248
Lease liability – noncurrent portion		191,130		221,873

The Company has lease liabilities related to the lease of its corporate offices. On September 30, 2022, the Company's lease on office space ended and a new lease agreement was entered into, effective November 1, 2022. The weighted average discount rate for the three months ended March 31, 2023, was 8% percent (December 31, 2022 – 8%).

The total future minimum rent payable under the Company's lease on March 31, 2023, was as follows:

Due in less than 1 year	$	150,248
Due between 1 and 3 years		225,371
Total lease payments		375,619
Amounts representing interest over the term of the lease		(34,241)
Present value of minimum lease payments	**$**	**341,378**

13. CONVERTIBLE DEBENTURES

The following table is a break down of the convertible debenture balance on initial recognition and subsequent accretion:

		March 31, 2023		December 31, 2022
Opening balance	$	1,861,201	$	-
Additions		1,006,187		1,199,085
Extinguishment		(1,062,000)		662,116
Converted to common shares		(876,000)		-
Accretion expense		95,759		-
Ending Balance	**$**	**1,025,147**	**$**	**1,861,201**

(ii) On January 28, 2022, the Company completed a convertible debenture offering through the issuance of 1,938 convertible debenture units, issued at a price of $800 per unit for gross proceeds of $1,550,400. Each debenture unit consists of an aggregate of $1,000 principal of secured subordinated convertible debentures of 545 common share purchase warrants.

The debentures will mature one year following the closing date. Each debenture shall be convertible at any time following the date that is year from the closing date, at the option of the holder, into common shares at a price of: (A) $1.20 per share, if converted between the period commencing year from the closing date and ending on the second business day prior to the maturity date; or (B) $0.85 per share, if converted anytime after the second business day prior to the maturity date. The debentures will not bear interest prior to the Maturity Date, after which they will bear interest at a rate of 15%.

Each common share purchase warrant is exercisable into one common share at a price of $1.10 per share for a period of three years from the closing date.

(Expressed in Canadian dollars)

13. CONVERTIBLE DEBENTURES (CONTINUED)

The portion of the proceeds will be allocated to the warrants and the conversion option, which has been accounted for as a derivative liability. The fair value assigned to the warrants was $206,255 and was determined using the Black-Scholes Option Pricing Model using the following variables: risk-free rate of 1.4%, volatility of 95.3%, expected life of 3 years, dividend yield 0% and share price of $0.47. Refer to note 17 for details on the fair value of the conversion option.

As a result, the Company recognized the following:

Convertible debenture	$	1,199,085
Issuance Costs		77,163
Warrants		206,255
Derivative liability (Note 15)		67,897
	$	**1,550,400**

On January 28, 2023, the Company entered into agreements with the holders of these to amend the terms of the debentures and warrants issued with the debentures. Debentures bearing an aggregate amount of $876,000 will have their conversion price amended from $0.85 to $0.40 per Common Share (the “repriced debentures”) while the remaining debentures bearing an aggregate amount of $1,062,000 will have their maturity date extended from January 28, 2023, to July 28, 2023 (the “extended debentures” and together with the repriced debentures, the “amended debentures”). A total of 3,439,409 common shares are issuable upon conversion of the amended debentures.

On the agreement date, the repriced debentures, with a value of $876,000, were converted into an aggregate of 2,190,000 common shares. Debentures with a face value of $1,062,000 were extinguished, given the extension was granted on the maturity date. A new convertible debenture was recorded accruing interest at 15% per annum. A portion of the face value allocated to the conversion option, which has been accounted for as a derivative liability. As a result, the Company recognized the following:

Convertible debenture	$	1,006,187
Derivative liability (Note 15)		55,813
	$	**1,062,000**

In conjunction with these amendments, the exercise price of the common share purchase warrants issued with the loan agreement was amended from $1.10 per common share to $0.55 per common share.

During the three months ended March 31, 2023, the Company recognized accretion expense of $95,759 (March 31, 2022 - $100,998) and interest expense of $27,247 (March 31, 2022 - $nil) in relation to these convertible debentures.

14. LOANS PAYABLE

		March 31, 2023		December 31, 2022
Opening balance	$	976,397	$	1,505,933
Repayments		(514,913)		(1,214,875)
Accretion		60,987		738,165
Foreign exchange translation		(80,984)		(52,826)
Ending Balance	**$**	**441,487**	**$**	**976,397**
Current	$	303,596	**$**	796,846
Non-current	$	137,891	**$**	179,551

(Expressed in Canadian dollars)

14. LOANS PAYABLE (CONTINUED)

Term loan

On August 18, 2021, the Company entered into a term loan agreement for principal of $2,118,000, incurring 5% interest for a term of 13 months. The loan principal is to be repaid in 12 equal monthly payments, beginning 2 months after the issuance date. The balance was recognized net of the following discounts and issuance costs:

Principal	$	2,118,000
Discount		(318,000)
Issuance Costs		(100,000)
Warrants		(577,060)
	$	**1,122,940**

As part of the term loan agreement, the Company issued 1,636,364 common share purchase warrants to the lender, exercisable into common shares of the Company for 3 years from the date of issuance at a price of $1.10 per common share. The fair value of the warrants was determined using the Black-Scholes pricing model with the following assumptions: risk-free rate of 0.55%, volatility of 98%, expected life of 1.5 years, dividend yield 0% and share price of $1.08.

On October 31, 2022, the Company entered into an extension agreement in connection with this term loan. Under the terms of the extension, the maturity date was extended by 5 months to March 19, 2023, accruing interest at the original rate of 5%. The Company will make monthly payments of $50,000 plus any accrued interest, with the balance paid in a lump sum on the maturity date. In addition, the Company will pay a fee equal to 15% of the amount extended. The fee is payable on the maturity date and does not accrue interest. In conjunction with the extension, the exercise price of the common share purchase warrants issued with the loan agreement was amended from $1.10 per common share to $0.55 per common share. As of March 31, 2023, the balance of the loan had been repaid with only the 15% fee outstanding.

During the three months ended March 31, 2023, the Company incurred accretion expense of $60,987 (March 31, 2022 - $180,618) and interest expense of $5,434 (March 31, 2022 - $16,134) in relation to this loan.

Bank loan

On October 28, 2021, the Company’s majority owned subsidiary, SMGH, received a bank loan from a financial institution in Colombia. SMGH borrowed principal of $659,086 (COL$2,000,000,000), incurring interest at 8.3% over a term of 3 years. The loan is to be repaid in 12 quarterly payments over the life of the loan.

During the three-months ended March 31, 2023, the Company incurred interest expense of $7,218 (March 31, 2022 - $12,977) in relation to this loan.

15. DERIVATIVE LIABILITIES

		March 31, 2023		December 31, 2022
Opening balance	$	972	$	-
Additions		55,813		67,897
Gain on change in fair value		(39,234)		(66,925)
Ending Balance	**$**	**17,551**	**$**	**972**

On January 28, 2022, the Company completed a convertible debenture offering (note 13). As there are more than one conversion price that investors can exercise at, the conversion option does not meet the fixed-for-fixed criteria under IFRS 9, and therefore is accounted for as a derivative liability at fair value through profit or loss. On the date of issuance, the conversion option had a fair value of $67,897 which was determined using the Black-Scholes option pricing model with the following variables: risk-free rate of 0.98%, volatility of 63.2%, expected life of 1 year, dividend yield 0%, share price of $0.47 and exercise price of $0.85 - $1.20.

(Expressed in Canadian dollars)

15. DERIVATIVE LIABILITIES (CONTINUED)

On January 28, 2023, the derivative liability was extinguished on the amendment of the debenture agreements (note 13) and replaced with a derivative liability consistent with the amended terms of the unconverted debentures. On the date of amendment, the derivative liability had a fair value of $55,813 which was determined using a Black-Scholes option pricing model with the following variables: risk-free rate of 3.85%, volatility of 112.53%, expected life of 0.5 years, dividend yield 0%, share price of $0.41 and exercise price of $0.85. For the three months ended March 31, 2023, a gain on the on the change in fair value of $39,234 was recognized (March 31, 2022 - $50,956).

16. RELATED PARTY TRANSACTIONS

The Company defines key management personnel as the Chief Executive Officer, Chief Legal Officer, Chief Financial Officer, and President of LATAM. The following outlines salaries and shared based compensation accrued or paid to key management personnel:

	For the three-months ended March 31, 2023	2022
Salaries	$ 161,932	$ 183,125
Stock-based compensation	416,256	83,770
	$ 578,188	**$ 266,895**

Additionally, as of March 31, 2023, the Company accumulated advances from certain related parties who represent the minority shareholders of SMGH in the amount of $4,192,795 (December 31, 2022- $3,843,196). The advances relate to minority partners contributions towards the expansion and operation of the cultivation facilities. The balance owed to the related party is interest free. As these amounts become due, the outstanding balances are converted into common shares of SMGH, consistent with current ownership splits. During the three-months ended March 31, 2023, $nil was converted into equity in SMGH (December 31, 2022 - $nil).

Changes in the balances are disclosed in the following table:

	March 31, 2023	December 31, 2022
Opening Balance	$ 3,843,196	$ 3,659,931
Additions	171,543	760,795
Foreign exchange	178,056	(577,530)
Ending Balance	**$ 4,192,795**	**$ 3,843,196**

17. SHARE CAPITAL

Authorized and outstanding share capital:

The authorized share capital of the Company consists of an unlimited number of common shares and an unlimited number of preferred shares with no par value. As of March 31, 2023, the Company had 83,198,475 common shares issued and outstanding (December 31, 2022 – 75,952,800).

[i] On March 31, 2022, the Company issued an aggregate of 7,210,194 Units (the “Units”) at a price of $0.35 per Unit for net proceeds of $2,491,068, comprised of aggregate gross proceeds of $2,523,568 less share issuance costs of $32,500. Each Unit was comprised of one (1) common share in the capital of the Company and one-half common share purchase warrant. Each whole Warrant is exercisable into one common share in the capital of the Company at a price of $0.40 until March 31, 2025.

As compensation related to this financing, the Company issued 92,857 broker warrants, exercisable into one common share in the capital of the Company at a price of $0.40 until March 31, 2025.

(Expressed in Canadian dollars)

17. SHARE CAPITAL (CONTINUED)

The net proceeds of $2,491,068 were allocated between the common shares and the warrants by determining the fair value of the warrants, and allocating the residual to the common shares as follows:

Common shares	$	1,959,837
Warrants		517,892
Broker warrants		13,339
	$	**2,491,068**

The fair value of the common share purchase warrants was determined using the Black-Scholes option pricing model with a market price per common share of $0.35, a risk-free interest rate of 2.28%, an expected annualized volatility of 94.73% and expected dividend yield of 0%.

[ii] On May 6, 2022, the Company issued an aggregate of 4,210,931 Units (the "Units") at a price of $0.35 per Unit for net proceeds of $1,428,826, comprised of aggregate gross proceeds of $1,473,826 less share issuance costs of $45,000. Each Unit was comprised of one (1) common share in the capital of the Company and one-half common share purchase warrant. Each whole Warrant is exercisable into one common share in the capital of the Company at a price of $0.40 until May 6, 2025.

The net proceeds of $1,428,826 were allocated between the common shares and the warrants by determining the fair value of the warrants, and allocating the residual to the common shares as follows:

Common shares	$	1,200,836
Warrants		227,990
	$	**1,428,826**

The fair value of the common share purchase warrants was determined using the Black-Scholes option pricing model with a market price per common share of $0.30, a risk-free interest rate of 2.75%, an expected annualized volatility of 95.89% and expected dividend yield of 0%.

[iii] On August 17, 2022, the Company issued an aggregate of 7,949,433 Units (the "Units") at a price of $0.35 per Unit for net proceeds of $2,782,301. Each Unit was comprised of one (1) common share in the capital of the Company and one-half common share purchase warrant. Each whole Warrant is exercisable into one common share in the capital of the Company at a price of $0.40 until August 17, 2025.

The net proceeds of $2,782,301 were allocated between the common shares and the warrants by determining the fair value of the warrants, and allocating the residual to the common shares as follows:

Common shares	$	2,147,209
Warrants		635,092
	$	**2,782,301**

The fair value of the common share purchase warrants was determined using the Black-Scholes option pricing model with a market price per common share of $0.36, a risk-free interest rate of 3.30%, an expected annualized volatility of 99.79% and expected dividend yield of 0%.

[iv] On November 10, 2022, the Company issued an aggregate of 1,790,750 Units (the "Units") at a price of $0.35 per Unit for net proceeds of $610,288, comprised of gross proceeds of $626,763 less issuance costs of $16,475. Each Unit was comprised of one (1) common share in the capital of the Company and one-half common share purchase warrant. Each whole Warrant is exercisable into one common share in the capital of the Company at a price of $0.40 until November 10, 2025.

(Expressed in Canadian dollars)

17. SHARE CAPITAL (CONTINUED)

The net proceeds were allocated between the common shares and the warrants by determining the fair value of the warrants, and allocating the residual to the common shares as follows:

Common shares	$	502,880
Warrants		102,925
Broker warrants		4,483
	$	**610,288**

The fair value of the common share purchase warrants and broker warrants was determined using the Black-Scholes option pricing model with a market price per common share of $0.30, a risk-free interest rate of 4.05%, an expected annualized volatility of 96.53% and expected dividend yield of 0%.

[v] On December 21, 2022, the Company issued an aggregate of 5,054,562 Units (the "Units") at a price of $0.35 per Unit for net proceeds of $1,763,597, comprised of gross proceeds of $1,769,097 less issuance costs of $5,500. Each Unit was comprised of one (1) common share in the capital of the Company and one-half common share purchase warrant. Each whole Warrant is exercisable into one common share in the capital of the Company at a price of $0.40 until December 21, 2025.

The net proceeds were allocated between the common shares and the warrants by determining the fair value of the warrants, and allocating the residual to the common shares as follows:

Common shares	$	1,379,097
Warrants		384,500
	$	**1,763,597**

The fair value of the common share purchase warrants was determined using the Black-Scholes option pricing model with a market price per common share of $0.37, a risk-free interest rate of 3.48%, an expected annualized volatility of 92.28% and expected dividend yield of 0%.

[vi] On March 20, 2023, the Company issued an aggregate of 3,096,230 Units (the "Units") at a price of $0.40 per Unit for net proceeds of $1,226,492, comprised of gross proceeds of $1,238,492 less issuance costs of $12,000. Each Unit was comprised of one (1) common share in the capital of the Company and one-half common share purchase warrant. Each whole Warrant is exercisable into one common share in the capital of the Company at a price of $0.50 until March 20, 2026.

The net proceeds were allocated between the common shares and the warrants by determining the fair value of the warrants, and allocating the residual to the common shares as follows:

Common shares	$	1,019,089
Warrants		204,822
Broker warrants		2,481
	$	**1,226,392**

The fair value of the common share purchase warrants was determined using the Black-Scholes option pricing model with a market price per common share of $0.37, a risk-free interest rate of 3.48%, an expected annualized volatility of 92.28% and expected dividend yield of 0%.

(Expressed in Canadian dollars)

17. SHARE CAPITAL (CONTINUED)

Warrant Reserve

As of March 31, 2023, the following warrants were outstanding and exercisable:

	Warrants	Weighted average exercise price
	#	$
Outstanding as of December 31, 2021	**14,864,615**	**1.40**
Warrants issued	14,295,997	0.15
Warrants expired	(2,612,413)	0.24
Outstanding as of December 31, 2022	**26,548,199**	**0.90**
Warrants issued	1,566,865	0.04
Warrants expired	(411,360)	0.03
Outstanding as of March 31, 2023	**27,703,704**	**0.85**

The following table is a summary of the Company's warrants outstanding as of March 31, 2023:

	Warrants Outstanding		Warrants Exercisable	
Exercise price range	Number outstanding	Weighted average remaining life	Weighted average exercise price	Number exercisable
$	#	(years)	$	#
1.20	3,430,967	0.12	0.15	3,430,967
1.75	4,480,000	0.19	0.28	4,480,000
1.10	2,293,511	0.15	0.09	2,293,511
0.55	2,692,574	0.17	0.05	2,692,574
0.50	1,566,865	0.18	0.03	1,566,865
0.40	13,239,787	1.23	0.19	13,239,787
	27,703,704	**2.04**	**0.79**	**27,703,704**

(Expressed in Canadian dollars)

18. SHARE BASED PAYMENT RESERVE AND COMPENSATION

The Company has established a Long-Term Omnibus Compensation Plan (the "Omnibus Plan") for directors, officers, employees, and consultants of the Company. The Company's Board of Directors determines, among other things, the eligibility of individuals to participate in the Option Plan and the term, vesting periods, and the exercise price of options and share units granted to individuals under the Omnibus Plan.

Each option converts into one common share of the Company on exercise. No amounts are paid or payable by the individual on receipt of the option. The options carry neither the right to dividends nor voting rights. Options may be exercised at any time from the date of vesting to the date of their expiry. Each share unit converts into a single common share of the Company on the vesting date. No amounts are payable on receipt of the share unit or at vesting.

The Company's Omnibus Plan provides that the number of common shares reserved for issuances of options may not exceed 10%, and the number of common shares reserved for the issuance of share units must not exceed 4%, of the number of common shares outstanding. If any options or share units terminate, expire, or are cancelled, as contemplated by the Omnibus Plan, the number of options or share units so terminated, expired, or cancelled shall again be available under the Omnibus Plan.

Share-based compensation is comprised of the following:

	For the three months ended March 31,			
		2023		**2022**
Stock options	$	34,767	$	53,617
Restricted Stock Units		962,700		99,625
	$	**997,467**	**$**	**153,242**

<u>Employee and non-employee options</u>

[i] Measurement of fair values

The fair value of share options granted during the Three Months Ended March 31, 2023, and 2022, was estimated at the date of grant using the Black Scholes option pricing model using the following inputs:

	2023	**2022**
Grant date share price	$0.48	-
Exercise price	$0.60	-
Expected dividend yield	0%	-
Risk-free interest rate	3.24%	-
Expected option life	2.5 years	-
Expected volatility	102.48%	-

Expected volatility was estimated by using the historical volatility of the Company's publicly traded common shares. The expected option life represents the period that options granted are expected to be outstanding. The risk-free interest rate is based on Canada government bonds with a remaining term equal to the expected life of the options.

(Expressed in Canadian dollars)

18. SHARE BASED PAYMENT RESERVE AND COMPENSATION (CONTINUED)

[ii] Options Issued and Outstanding

	Options	Weighted average exercise price
	#	$
Outstanding on December 31, 2021	**1,496,489**	**2.39**
Options issued	90,000	0.37
Options cancelled and forfeited	(53,692)	1.78
Outstanding on December 31, 2022	**1,532,797**	**2.29**
Options issued	625,000	0.60
Outstanding on March 31, 2023	**2,157,797**	**1.80**

During the three months ended March 31, 2023, the Company recognized a total share-based compensation expense relating to options of $34,767 (March 31, 2022 - $53,617).

The following table is a summary of the Company's share options outstanding as of March 31, 2023:

	Options Outstanding		Options Exercisable	
Exercise price range	**Number outstanding**	**Weighted average remaining life**	**Weighted average exercise price**	**Number exercisable**
$	#	(years)	$	#
0.37	90,000	0.19	0.02	-
0.60	625,000	1.38	0.17	-
1.00	686,666	1.18	0.32	686,666
1.24	4,167	0.01	0.00	4,167
1.39	13,000	0.02	0.01	13,000
2.00	265,000	0.25	0.25	265,000
2.50	81,002	0.24	0.09	81,002
2.75	202,867	0.27	0.26	202,867
5.00	14,595	0.01	0.03	14,595
7.30	2,000	0.00	0.01	2,000
8.00	173,500	0.21	0.64	173,500
	2,157,797	**3.56**	**1.80**	**1,442,797**

Restricted Stock Units

The fair value of restricted stock units ("RSUs") granted is based on the market price of the Company's publicly traded common shares on the grant date.

(Expressed in Canadian dollars)

18. SHARE BASED PAYMENT RESERVE AND COMPENSATION (CONTINUED)

The following table summarized the continuity of the Company's RSUs:

	RSUs	Weighted average issue price
	#	$
Outstanding on December 31, 2021	**742,008**	**2.30**
RSUs vested	(2,782,562)	0.52
RSUs issued	3,147,435	0.33
RSUs forfeited and cancelled	(13,000)	1.25
Outstanding on December 31, 2022	**1,093,881**	**1.45**
RSUs vested [i]	(2,959,444)	0.50
RSUs issued [ii]	3,559,731	0.43
Outstanding on March 31, 2023	**1,694,168**	**0.41**

[i] During the three months ended March 31, 2023, 2,959,444 common shares were issued on the vesting of restricted stock units. The grant price of the exercised units ranged from $0.37 to $1.25.

[ii] During the three months ended March 31, 2023, 3,559,731 restricted stock units were issued with a fair value of between $0.37 - $0.48 per unit. Of the units issued, 2,604,571 vested immediately and 955,160 vest over two years.

During the three months ended March 31, 2023, the Company recognized a total share-based compensation expense relating to restricted stock units of $962,700 (March 31, 2022 - $99,625).

19. NON-CONTROLLING INTEREST

The net change in non-controlling interest is as follows:

		March 31, 2023		December 31, 2022
Opening Balance	$	3,842,211	$	5,761,835
Sale of Sativa Nativa S.A.S.		-		247,158
Foreign translation		(36,583)		(353,261)
Net loss attributed to non-controlling interest		(86,224)		(1,313,521)
Ending Balance	**$**	**3,719,404**	**$**	**3,842,211**

20. FINANCIAL RISK MANAGEMENT AND FINANCIAL INSTRUMENTS

Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from deposits with banks and outstanding receivables. The Company does not hold any collateral as security but mitigates this risk by dealing only with what management believes to be financially sound counterparties and, accordingly, does not anticipate significant loss for non-performance.

As of March 31, 2023, $1,965,414 in trade and other receivables remained outstanding (December 31, 2022 – $2,121,619). The Company applies the simplified approach to providing for expected credit losses as prescribed by IFRS 9, which permits the use of lifetime expected loss provision for all trade receivables. The loss allowance is based on the Company's historical collection and loss experience and incorporates forward-looking factors, where appropriate.

During the three-months ended March 31, 2023, the Company has recognized an estimated credit losses of $16,454 (March 31, 2022 – $nil).

(Expressed in Canadian dollars)

20. FINANCIAL RISK MANAGEMENT AND FINANCIAL INSTRUMENTS (CONTINUED)

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company's exposure to liquidity risk is dependent on the Company's ability to raise additional financing to meet its commitments and sustain operations. The Company mitigates liquidity risk by management of working capital, cash flows and the issuance of share capital.

In addition to the commitments disclosed, the Company is obligated to the following contractual maturities of undiscounted cash flows:

	Carrying amount	Contractual cash flows	Year 1	Year 2	Year 3 +
Trade payables and accrued liabilities	$ 4,689,453	$ 4,689,453	$ 4,689,453	$ -	$ -
Loan payable	441,487	437,021	299,129	137,891	-
Convertible debentures	1,025,147	1,062,000	1,062,000	-	-
Lease liability	341,378	375,619	150,248	150,248	75,124
	$ 6,497,465	**$ 6,564,093**	**$ 6,200,830**	**$ 288,139**	**$ 75,124**

The due to related party balance of $4,192,795 is not intended to be repaid. As these amounts become due, the outstanding balances can be converted into common shares of SMGH, consistent with current ownership splits.

Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: currency rate risk, interest rate risk and other price risk.

Currency risk

Currency risk is the risk to the Company's earnings that arise from fluctuations in foreign exchange rates. The Company is exposed to foreign currency exchange risk as it has substantial operations based out of Colombia and record keeping is denominated in a foreign currency. As such the company has foreign currency risk associated with Colombian Pesos.

Interest risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to interest rate as all borrowing have fixed rates of interest which are not effected by these fluctuations. Loan payable, convertible debentures and lease liability are recorded at amortized cost using fixed interest rates.

(Expressed in Canadian dollars)

20. FINANCIAL RISK MANAGEMENT AND FINANCIAL INSTRUMENTS (CONTINUED)

Other price risk

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices of the Company's cannabis products (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market.

Fair values

The carrying values of cash, amounts receivable, investments, amounts payable, current portion of loan payable and convertible debentures, approximate the fair values due to the short-term nature of these items. The risk of material change in fair value is not considered to be significant due to the short-term nature. It is not practicable to estimate the fair value of the balance due to related party, due to the nature of this liability. The Company does not use derivative financial instruments to manage this risk.

Financial instruments recorded at fair value on the condensed consolidated interim statement of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The Company categorizes its fair value measurements according to a three-level hierarchy as disclosed in Note 22 to the Consolidated Financial Statements for the year ended December 31, 2022. The hierarchy prioritizes the inputs used by the Company's valuation techniques. A level is assigned to each fair value measurement based on the lowest-level input significant to the fair value measurement in its entirety.

The Company's finance team performs valuations of financial items for financial reporting purposes, including level 3 fair values, in consultation with third party valuation specialists for complex valuations. Valuation techniques are selected based on the characteristics of each instrument, with the overall objective of maximizing the use of market – based information.

The fair value hierarchy requires the use of observable market inputs whenever such inputs exist. A financial instrument is classified to the lowest level of the hierarchy for which a significant input has been considered in measuring fair value. Warrants and derivative liability are classified as a level 2 financial instrument. As of the three months ended March 31, 2023, and the year ended December 31, 2022, there were no level 3 financial instruments.

21. GENERAL AND ADMINISTRATIVE EXPENSES

	For the three-months ended March 31, 2023	For the three-months ended March 31, 2022
Office and general	$ 424,126	$ 362,999
Selling marketing and promotion	74,256	65,823
Consulting fees	222,162	393,551
Professional fees	232,643	154,042
Salaries and wages	716,721	1,042,753
Research	107,994	26,319
	$ 1,777,902	**$ 2,045,487**

During the three-months ended March 31, 2023, as part of its inventory costing process, the Company capitalized $55,575 of salaries to inventory and biological assets (March 31, 2022 – $76,516).

(Expressed in Canadian dollars)

22. SEGMENT REPORTING

Operating segments are determined based on internal reporting that is regularly reviewed by the chief operating decision maker ("CODM") for the purpose of allocating resources to the segment and for assessing its performance. As of March 31, 2023, the Company determined that it has four operating segments, three organized by geographical area: North America, South America, and rest of world, and Corporate, comprised of costs which serve the Company's global administrative responsibilities.

North America includes sales of the Company's pharmaceutical and health products as well as revenue generated from the licensing of intellectual property and research and development services, all developed in North America and serving customers within Canada and the United States. South America includes sales of the Company's pharmaceutical and health products and sales of API to customers worldwide, all grown and developed in Colombia. Rest of world includes sales of products to customers in Europe and Central America. Corporate includes overhead and financing costs incurred by the Company to support its public company infrastructure and operating segments.

	North America	South America	Rest of World	Corporate	Total
Statement of Financial Position					
As of March 31, 2023					
Current assets	$ 3,099,855	$ 3,817,995	$ 79,730	$ -	$ 6,997,580
Non-current assets	636,066	10,216,383	-	-	10,852,449
Current liabilities	(4,637,425)	(5,719,526)	(21,839)	-	(10,378,790)
Non-current liabilities	(2,441,043)	(137,892)	-	-	(2,578,935)
As of December 31, 2022					
Current assets	$ 2,933,367	$ 4,052,662	$ 78,389	$ -	$ 7,064,418
Non-current assets	701,862	9,852,951	-	-	10,554,813
Current liabilities	(5,967,677)	(5,426,210)	(11,372)	-	(11,405,259)
Non-current liabilities	(2,575,769)	(179,552)	-	-	(2,755,321)

	North America	South America	Rest of World	Corporate	Total
Statement of Operations and Comprehensive Loss					
Three Months Ended March 31, 2023					
Revenue	$ 1,057,586	$ 112,632	$ -	$ -	$ 1,170,218
Gross margin	445,520	142,436	-	-	587,956
Operating expenses	(970,140)	(627,673)	(3,779)	(1,348,162)	(2,949,754)
Net loss before tax	(690,769)	(465,645)	(3,779)	(1,348,162)	(2,508,355)
Three Months Ended March 31, 2022					
Revenue	$ 845,572	$ 176,218	$ 16,171	$ -	$ 1,037,961
Gross margin	310,373	1,484,513	5,601	-	1,800,487
Operating expenses	(901,390)	(952,394)	(32,323)	(566,092)	(2,452,199)
Net loss before tax	(852,483)	505,496	(25,997)	(566,092)	(939,076)

(Expressed in Canadian dollars)

23. NON-CASH OPERATING ELEMENTS OF WORKING CAPITAL

	For the Three Months Ended March 31			
		2023		**2022**
Amounts receivable	$	(324,718)	$	(688,479)
Biological assets		127,948		649,175
Inventory		(324,756)		(2,202,295)
Prepaid assets		(400,256)		198,806
Accounts payable		188,464		(699,441)
	$	**(733,318)**	**$**	**(2,742,234)**

24. DIVESTITURE OF SATIVA NATIVA S.A.S.

On June 29, 2022, the Company and the non-controlling shareholders (collectively the “Shareholders”) of Sativa Nativa S.A.S (“SN”), closed an agreement to divest 100% of the outstanding common shares of SN to an unrelated third-party. SN operates a farm and processing facility in Santa Marta, Colombia and has licenses to harvest and extract medical cannabis in Colombia.

Pursuant to the agreement, the Shareholders received a cash payment of USD$883,075 ($1,137,935). The Shareholders are also entitled to additional funds of USD$170,000 ($219,063) upon successful transfer of the processes and technology. The Company’s compensation as a result of this transaction was USD$519,513 ($669,446) cash and additional cash consideration of USD$98,600 ($127,056) which is proportional to the Company’s ownership share of 63%.

Following the SN divestiture, the Company no longer controls SN and the Company derecognized the assets and liabilities of SN from the Condensed consolidated interim financial statements, at their carrying amounts. Pursuant to the agreement with the acquirer, the balances owed to the Company, will be forgiven. The derecognized assets and liabilities on June 29, 2022, were as follows:

Current assets	$	(448,246)
Capital assets		(1,270,071)
Current liabilities		1,918,563
Cumulative translation adjustment		425,405
	$	625,651
Consideration received in cash		1,137,935
Future cash consideration		219,063
Proportion of compensation allocated to non-controlling interests		(560,494)
	$	796,504
Forgiveness of balance receivable by Avicanna Inc.	$	(2,953,149)
Loss on sale of Sativa Nativa S.A.S.	**$**	**(1,530,994)**

The loss calculated on the derecognition of SN’s assets and liabilities is the difference between the carrying amounts of the derecognized assets and liabilities, inclusive of any cumulative translation adjustment amounts and the fair value of the consideration received.